Oncolytic viruses for the treatment of malignant glioma

Expert Opinion on Therapeutic Patents

Volumn 16, Issue 3, 2006, Pages 363-371

  Merrill, Melinda K ^a   Selznick, Lee A ^a   Gromeier, Matthias ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Adenovirus; Glioma; Herpesvirus; Myxoma virus; Newcastle disease virus; Oncolytic virus; Poliovirus; Reovirus

Indexed keywords

ANTINEOPLASTIC AGENT; G 207; HSV 1716; MTH 68 H; ONYX 015; PV 701; R 5111; REOLYSIN; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ADENOVIRUS; CANCER CELL; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER SURVIVAL; CLINICAL TRIAL; CRANIECTOMY; CYTOLYSIS; CYTOTOXICITY; DEATH; DRUG TARGETING; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL INFECTION; GENE THERAPY; GENETIC ENGINEERING; GLIOBLASTOMA; GROWTH INHIBITION; HERPES SIMPLEX VIRUS 1; HUMAN; IMMUNOMODULATION; INJECTION SITE NECROSIS; MEASLES VIRUS; MEDICAL LITERATURE; MOUSE; MULTIMODALITY CANCER THERAPY; NEUROSURGERY; NEWCASTLE DISEASE PARAMYXOVIRUS; NONHUMAN; ONCOLYTIC VIRUS; PATENT; POLIOMYELITIS VIRUS; PROGNOSIS; RECOMBINANT DNA TECHNOLOGY; REOVIRUS; RESPIRATORY TRACT INFECTION; REVIEW; TREATMENT OUTCOME; TUMOR VOLUME; UNSPECIFIED SIDE EFFECT; VIRUS REPLICATION;

EID: 33644886594     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.16.3.363     Document Type: Review

References (61)

1. MUNDSCHAU LJ, FALLER DV: Oncogenic Ras induces air inhibitor of double-stranded RNA-dependent eukarvotic initiation factor 2a-kinase activation. J. Biol. Chem. (1992) 267:23092-23098.
2. STRONG JE, COFFEY MC, TANG D, SABININ P, LEE PW: The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. EMBO J. (1998) 17:3351-3362.
3. NORMAN KL, HIRASAWA K, YANG AD, SHIELDS MA, LEE PW: Reovirus oncolysis: the Ras/RalGEF/p38 pathway dictates host cell permissiveness to reovirus infection. Proc. Natl. Acad. Sci. USA (2004) 101:11099-11104.
4. NISHIKAWA R, JI XD, HARMON RC et al.: A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicitiy. Proc. Natl. Acad. Sci. USA (1994) 91:7729-7731.
5. NISTER M, CLAESSON-WELSH L, ERIKSSON A, HELDIN CH, WESTERMARK B: Differential expression of platelet-derived growth factor receptors in human malignant glioma cell lines. J. Biol. Chem. (1991) 266:16755-16763.
6. COFFEY MC, STRONG JF, FORSYTH PA, LEE PW: Reovirus therapy of rumors with activated Ras pathway. Science (1998) 282:1332-1334.
7. WILCOX ME, YANG W, SENGER D et al.: Reovirus as an oncolytic agent against experimental human malignant gliomas. J. Natl. Cancer Inst. (2001) 93:903-912.
8. CASSEL WA, GARRETT RE: Newcastle disease virus as an antineoplastic agent. Cancer (1965) 18:863-868.
9. REICHARD KW, LORENCE RM, CASCINO CJ et al.: Newcastle disease virus selectively kills human tumor cells. J. Surg. Res. (1992) 52:448-453.
10. CSATARY LK, GOSZTONYI G, SZEBERENYI J et al.: MTH-68/H oncolytic viral treatment in human high-grade gliomas. J. Neurooncol. (2004) 67:83-93.
11. LORENCE RM, KATUBIG BB, REICHARD KW et al.: Complete regression of human fibrosarcoma xenografts after local Newcastle disease virus therapy. Cancer Res. (1994) 54:6017-6021.
12. LORENCE RM, REICHARD KW, KATUBIG BB et al.: Complete regression of human neuroblastoma xenografts in athymic mice after local Newcastle disease virus therapy. J. Natl. Canc. Inst. (1994) 86:1228-1233.
13. PHUANGSAB A, LORENCE RM, REICHARD KW, PEEPLES ME, WALTER RJ: Newcastle disease virus therapy of human tumor xenografts: antitumor effects of local or systemic administration. Cancer Lett. (2001) 72:27-36.
14. PECORA AL, RIZVI N, COHEN GI et al.: Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J. Clin. Oncol. (2002) 20:2251-2266.
15. JACKSON EW, DORN CR, SAITO JK, MCKERCHER DG: Absence of serological evidence of myxoma virus infection in humans exposed during an outbreak of myxomatosis. Nature (1966) 211:313-314.
16. SYPULA J, WANG F, MA Y, BELL J, MCFADDEN G: Myxoma virus tropism in human tumor cells. Gene Ther. Mol. Biol. (2004) 8:103-114.
17. LUN X, YANG W, ALAIN T et al.: Myxoma virus is a novel oncolytic virus with significant antitumor activity against experimental human gliomas. Cancer Res. (2005) 65:9982-9990.
18. WANG F, MA Y, BARRETT JW et al.: Disruption of Erk-dependent Type I interferon induction breaks the myxoma virus species barrier. Nat. Immunol. (2004) 5:1266-1274.
19. JOHNSTON JB, BARRETT JW, CHANG W et al.: Role of the serine-threonine kinase PAK-1 in myxoma virus replication. J. Virol. (2003) 77(10):5877-5888.
20. JOHNSTON JB, NAZARIAN SH, NATALE R, MCFADDEN G: Myxoma virus infection of primary human fibroblasts varies with cellular age and is regulated by host interferon responses. Virology (2005) 332(1):235-248.
21. HUEBNER RJ, ROWE WP, SCHATTEN WE, SMITH RR, THOMAS LB: Studies on the rise of viruses in the treatment of carcinoma of the cervix. Cancer (1956) 9:1211-1218.
22. HEISE C, SAMPSON-JOHANNES A, WILLIAMS A, MCCORMICK F, VON HOFF DD, KIRN DH: ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med. (1997) 3:639-645.
23. QUERIDO E, MARCELLUS RC, LAI A et al.: Regulation of p53 levels by the E1B 55-kilodalton protein and E4orf in adenovirus infected cells. J. Virol. (1997) 71:3788-3798.
24. MOORE M, HORIKOSHI N, SHENK T: Oncogenic potential of the adenovirus E4orf6 protein. Proc. Natl. Acad. Sci. USA (1996) 93:11295-11301.
25. BABISS LE, GINSBERG HS, DARNELL JE JR: Adenovirus E1B proteins are required for accumulation of late viral mRNA and for effects on cellular mRNA translation and transport. Mol. Cell Biol. (1985) 5:2552-2558.
26. GOODRUM F, ORNELLES D: p53 status does not determine outcome of E1B55-kilodalton mutant adenovirus lytic infection. J. Virol. (1998) 72:9479-9490.
27. ROTHMANN T, HENGSTERMANN A, WHITAKER NJ, SCHEFFNER M, ZUR HAUSEN H: Replication of ONYX-015, a potential anti-cancer adenovirus is independent of p53 status in tumor cells. J. Virol. (1998) 72:9470-9478.
28. HARDA JN, BERK AJ: p53-independcnt and -dependent requirements for E1B-55K in adenovirus Type 5 replication. J. Virol. (1999) 73:5333-5344.
29. BELL JC, LICHTY B, STOJDL D: Getting oncolytic virus therapies off the ground. Cancer Cell (2003) 4:7-11.
30. SHEN Y, KITZES G, NYE JA, FATTAEY A, HERMISTON T: Analyses of single amino acid substitution mutants of adenovirus Type 5 E1B-55K protein. (2001) 75:4297-4307.
31. GEOERGER B, GRILL J, OPOLON P et al.: Oncolytic activity of the E1B-55 kda-deleted adenovirus ONYX-015 is independent of cellular p53 status in human malignant glioma xenogfafts. Cancer Res. (2002) 62:764-772.
32. FUEYO J, GOMEZ-MANZANO C, ALEMANY R et al.: A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene (2000) 19:2-12.
33. HEISE C, HERMISTON T, JOHNSON L et al.: An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat. Med. (2000) 6:1134-1139.
34. GHOSH S, DUIGOU GJ: Decreased replication ability of E1 deleted adenoviruses correlates with increased brain tumor malignancy. Cancer Res. (2005) 65:8936-8943.
35. FUEYO J, ALEMANY R, GOMEZ-MANZANO C et al.: Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. J. Natl. Cancer Inst. (2003) 95:652-660.
36. GROMEIER M, ALEXANDER L, WIMMER E: Internal ribosomal entry site substitution eliminates neurovirulence in intergenic poliovirus recombinants. Proc. Natl. Acad. Sci. USA (1996) 93:2370-2375.
37. GROMEIER M, LACHMANN S, ROSENFELD MR, GUTIN PH, WIMMER E: Intergenic poliovirus recombinants for the treatment of malignant glioma. Proc. Natl. Acad. Sci. (2000) 97:6803-6808.
38. GROMEIER M, BOSSERT B, ARITA M, NOMOTO A, WIMMER E: Dual stem loops within the poliovirus internal ribosomal entry site control neurovirulence. J. Virol. (1999) 73:958-964.
39. MERRILL M, BERNHARDT G, SAMPSON JH, WIKSTRAND CJ, BIGNER DD, GROMEIER M: Poliovirus receptor CD155-targeted oiicolysis of glioma. Neuro-oncology (2004) 6:208-217.
40. RAMPLING R, CRUICKSHANK G, PAPANASTASSIOU V et al.: Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther. (2000) 7:859-866.
41. PAPANASTASSIOU V, RAMPLING R, FRASER M et al.: The potential for efficacy of the modified [ICP 34.5 (-)] herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study. Gene Ther. (2002) 9:398-406.
42. HARROW S, PAPANASTASSIOU V, HARLAND J et al.: HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma safety data and long-term survival. Gene Ther. (2004) 11:1648-1658.
43. CASSADY KA, GROSS M, ROIZMAN B: The second-site mutation in the herpes simplex virus recombinants lacking the γ-34.5 genes precludes shutoff of protein synthesis by blocking the phosphorylation of eIF-2α. J. Virol. (1998) 72:7005-7011.
44. MINETA T, RABKIN SD, YAZAKI T, HUNTER WD, MARTUZA RL: Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat. Med. (1995) 9:938-943.
45. ELLEDGE SJ, ZHOU Z, ALLEN JB: Ribonucleotide reductase: regulation, regulation, regulation. Trends Biochem. Sci. (1992) 17:119-123.
46. MARKERT JM, MEDLOCK MD, RABKIN SD et al.: Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a Phase I trial. Gene Ther. (2000) 7:867-874.
47. DEBINSKI W, GIBO DM, SLAGLE B, POWERS SK, GILLESPIE GY: Receptor for interleukin-13 is abundantly and specifically over-expressed in patients with glioblastoma multiforme. Int. J. Oncol. (1999) 15:481-486.
48. KAWAKAMI M, KAWAKAMI K, TAKAHASHI S, ABE M, PURI RK: Analysis of interleukin-13 receptor α2 expression in human pediatric brain tumors. Cancer (2004) 101:1036-1042.
49. KAWAKAMI K, TAGUCHI J, MURATA I, PURI RK: The interleukin-13 receptor 2 chain: an essential component for binding and internalization but not for interleukin-13-induced signal transduction through the STAT6 pathway. Blood (2001) 97:2673-2679.
50. WOOD N, WHITTERS MJ, JACOBSON BA et al.: Enhanced interleukin (IL)-13 responses in mice lackiiig IL-13 receptor α2. J. Exp. Med. (2003) 197:703-709.
51. ZHOU G, YE GJ, DEBINSKI W, ROIZMAN B: Engineered herpes simplex virus 1 is dependent on IL13Rα2 receptor for cell entry and independent of glycoprotein D receptor interaction. Proc. Natl. Acad. Sci. USA (2002) 99:15124-15129.
52. ZHOU G, ROIZMAN B: Characterization of a recombinant herpes simplex virus 1 designed to enter cells via the IL13Rα2 receptor of malignant glioma cells. J. Virol. (2005) 79:5272-5277.
53. DOUGLAS J, KIM M, SUMEREL L, CAREY D, CURIEL D: Efficient oncolysis by a replicating adenovirus in vivo is critically dependent on tumor expression of primary Ad receptors. Cancer Res. (2001) 61:813-817.
54. RANCOURT C, ROGERS BE, SOSNOWSKI BA et al.: Basic fibroblast growth factor enhancement of adenovirus-mediated delivery of the herpes simplex virus thymidine kinase gene results in augmented therapeutic benefit in a murine model of ovarian cancer. Clin. Cancer Res. (1998) 4:2455-2461.
55. STERMAN DH, TREAT J, LITZKY LA et al.: Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a Phase I clinical trial in malignant mesothelioma. Hum. Gene Ther. (1998) 9:1083-1092.
56. BENNETT JJ, ADUSUMILLI P, PETROWSKY H et al.: Up-regulation of GADD34 mediates the synergistic anticancer activity of mitomycinl C and a γ-134.5 deleted oncolytic herpes virus (G207). FASEB J. (2004) 18:1001-1003.
57. CHAHLAVI A, TODO T, MARTUZA RL, RABKIN SD: Replication-competent Herpes Simplex Virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma. Neoplasia (1999) 1:162-169.
58. HALL WA, RUSTAMZADEH E, ASHER AL: Convection-enhanced delivery in clinical trials. Neurosurg. Focus (2003) 14:e2.
59. KAWAKAMI K, KAWAKAMI M, KIOI M, HUSAIN SR, PURI RK: Distribution kinetics of targeted cytotoxin in glioma by bolus or convection-enhanced delivery in a murine model. J. Neurosurg. (2004) 101:1004-1011.
60. BOIARDI A, EOLI M, SALMAGGI A et al.: Local drug delivery in recurrent malignant gliomas. Neurol. Sci. (2005) 26:S37-S39.
61. PATEL SJ, SHAPIRO WR, LASKE DW et al.: Safety and feasibility of convection-enhanced delivery of Cotara for the treatment of malignant glioma: initial experience in 51 patients. Neurosurgery (2005) 56:1243-1252.